Discrepancy between long-term and previously published analysis for osteonecrosis of the jaw under denosumab.
Department of Pharmacovigilance and Pharmacoepidemiology, Reims University Hospitals, Avenue du Général Koenig, 51100, Reims, France. pdeboissieu@chu-reims.fr.|Faculty of Medicine, University of Reims Champagne-Ardenne, EA3797, Reims, France. pdeboissieu@chu-reims.fr.
Paul
P
de Boissieu
Department of Pharmacovigilance and Pharmacoepidemiology, Reims University Hospitals, Avenue du Général Koenig, 51100, Reims, France.|Faculty of Medicine, University of Reims Champagne-Ardenne, EA3797, Reims, France.
Thierry
T
Trenque
D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw; D050071:Bone Density Conservation Agents; D000069448:Denosumab; D004164:Diphosphonates; D006801:Humans; D007571:Jaw Diseases; D010020:Osteonecrosis
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D000069448:Denosumab